A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Background: Ponatinib has been established as an optimal salvage treatment option in chronic myeloid leukemia (CML) patients who fail to second generation tyrosine kinase inhibitors (2GTKIs) or harbor T315I mutations. However, serious adverse events, mainly cardiovascular (CVS) events, have been related to ponatinib use at the standard dose (45 mg/day), and therefore dose reductions have been suggested for those patients achieving optimal responses. Clinical trials are currently evaluating different dose schemes in order to answer whether dose modifications could diminish side effects while maintaining responses.